JP2018531280A5 - - Google Patents

Download PDF

Info

Publication number
JP2018531280A5
JP2018531280A5 JP2018529503A JP2018529503A JP2018531280A5 JP 2018531280 A5 JP2018531280 A5 JP 2018531280A5 JP 2018529503 A JP2018529503 A JP 2018529503A JP 2018529503 A JP2018529503 A JP 2018529503A JP 2018531280 A5 JP2018531280 A5 JP 2018531280A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
acceptable salt
appendix
salt
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018529503A
Other languages
English (en)
Japanese (ja)
Other versions
JP6880023B2 (ja
JP2018531280A6 (ja
JP2018531280A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/048643 external-priority patent/WO2017035331A1/en
Publication of JP2018531280A publication Critical patent/JP2018531280A/ja
Publication of JP2018531280A6 publication Critical patent/JP2018531280A6/ja
Publication of JP2018531280A5 publication Critical patent/JP2018531280A5/ja
Priority to JP2021077099A priority Critical patent/JP7134294B2/ja
Application granted granted Critical
Publication of JP6880023B2 publication Critical patent/JP6880023B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018529503A 2015-08-25 2016-08-25 改善された特性を有するβ−グアニジノプロピオン酸の薬学的に許容される塩及びその使用 Active JP6880023B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021077099A JP7134294B2 (ja) 2015-08-25 2021-04-30 改善された特性を有するβ－グアニジノプロピオン酸の薬学的に許容される塩及びその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562209624P 2015-08-25 2015-08-25
US62/209,624 2015-08-25
PCT/US2016/048643 WO2017035331A1 (en) 2015-08-25 2016-08-25 PHARMACEUTICALLY ACCEPTABLE SALTS OF β-GUANIDINOPROPIONIC ACID WITH IMPROVED PROPERTIES AND USES THEREOF

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021077099A Division JP7134294B2 (ja) 2015-08-25 2021-04-30 改善された特性を有するβ－グアニジノプロピオン酸の薬学的に許容される塩及びその使用

Publications (4)

Publication Number Publication Date
JP2018531280A JP2018531280A (ja) 2018-10-25
JP2018531280A6 JP2018531280A6 (ja) 2018-12-13
JP2018531280A5 true JP2018531280A5 (enExample) 2019-10-03
JP6880023B2 JP6880023B2 (ja) 2021-06-02

Family

ID=58100994

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018529503A Active JP6880023B2 (ja) 2015-08-25 2016-08-25 改善された特性を有するβ−グアニジノプロピオン酸の薬学的に許容される塩及びその使用
JP2021077099A Active JP7134294B2 (ja) 2015-08-25 2021-04-30 改善された特性を有するβ－グアニジノプロピオン酸の薬学的に許容される塩及びその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021077099A Active JP7134294B2 (ja) 2015-08-25 2021-04-30 改善された特性を有するβ－グアニジノプロピオン酸の薬学的に許容される塩及びその使用

Country Status (16)

Country Link
US (4) US20170056352A1 (enExample)
EP (1) EP3340973B1 (enExample)
JP (2) JP6880023B2 (enExample)
KR (1) KR102707964B1 (enExample)
CN (2) CN108472269B (enExample)
AU (1) AU2016311368B2 (enExample)
CA (1) CA2996520C (enExample)
DK (1) DK3340973T3 (enExample)
ES (1) ES2843561T3 (enExample)
HR (1) HRP20210044T1 (enExample)
HU (1) HUE053963T2 (enExample)
PL (1) PL3340973T3 (enExample)
PT (1) PT3340973T (enExample)
RS (1) RS61804B1 (enExample)
SI (1) SI3340973T1 (enExample)
WO (1) WO2017035331A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3137447B1 (en) 2014-04-30 2021-06-30 Rgenix, Inc. Inhibitors of creatine transport and uses thereof
WO2016100619A2 (en) * 2014-12-17 2016-06-23 Rgenix, Inc. Treatment and diagnosis of cancer
US20170056352A1 (en) * 2015-08-25 2017-03-02 Rgenix, Inc. PHARMACEUTICALLY ACCEPTABLE SALTS OF beta-GUANIDINOPROPIONIC ACID WITH IMPROVED PROPERTIES AND USES THEREOF
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
WO2018160178A1 (en) * 2017-03-01 2018-09-07 Rgenix, Inc. Pharmaceutically acceptable salts of b-guanidinopropionic acid with improved properties and uses thereof
EP3713575A4 (en) 2017-11-21 2021-08-25 Rgenix, Inc. POLYMORPHS AND THEIR USES
CA3161341A1 (en) 2019-12-11 2021-06-17 Masoud Fakhr Tavazoie Methods of treating cancer
JP7689964B2 (ja) 2019-12-13 2025-06-09 インスピルナ，インコーポレーテッド 金属塩及びその使用
KR102615692B1 (ko) 2021-10-13 2023-12-19 주식회사 휴엔켐 베타-구아니디노프로피온산을 포함하는 간섬유화 예방 또는 치료용 조성물
EP4511349A1 (en) * 2022-04-21 2025-02-26 Merck Sharp & Dohme LLC Process for preparing agglomerated crystalline medium-chain fatty acid sodium salts
KR102822799B1 (ko) 2022-11-09 2025-06-20 충남대학교산학협력단 베타-구아니디노프로피온산을 포함하는 장내 미생물 개선용 조성물

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA101653A (en) 1906-08-30 1906-10-23 Herman Besser Mould
BE794886A (fr) * 1972-02-22 1973-08-02 Pfizer Acides 6-(alpha-(omega-guanidinoalcanoylamino)acylamino)-penicillaniques
US3933797A (en) * 1972-02-22 1976-01-20 Pfizer Inc. 6-[α-(ω-QUANIDINOALKANOYLAMIDO)ACYLAMIDO]PENICILLANIC ACIDS
US3972872A (en) 1974-09-23 1976-08-03 Pfizer Inc. 6-[α-(ω-Guanidinoalkanoylamido)acylamido]penicillanic acids
KR960004900B1 (ko) 1986-09-10 1996-04-17 신텍스(유.에스.에이.) 인코포레이티드 디아민의 선택적 아미딘화 방법
US5676978A (en) * 1989-02-14 1997-10-14 Amira, Inc. Methods of inhibiting undesirable cell growth using a combination of a cyclocreatine compound and a hyperplastic inhibitory agent
CA2028593C (en) * 1989-10-31 2007-08-21 Douglas R. Brandt Stabilized enzyme compositions
DE4334639A1 (de) 1993-10-11 1995-04-13 Inst Neue Mat Gemein Gmbh Verfahren zur Herstellung von TiN-Sinterkörpern und -Schichten
PT793646E (pt) 1994-11-23 2002-03-28 Biovitrum Ab Carboxilatos de aminoguanidina destinados ao tratamento de diabetes mellitus nao-insulinodependente
US5994577A (en) 1994-11-23 1999-11-30 Larsen; Scott D. Aminoguanidine carboxylates for the treatment of non-insulin-dependent diabetes mellitus
JP3745439B2 (ja) 1995-07-06 2006-02-15 花王株式会社 皮膚外用剤
TW453881B (en) 1995-10-16 2001-09-11 Kao Corp Cosmetic composition comprising amide derivatives
JPH09202710A (ja) * 1995-11-20 1997-08-05 Kao Corp しわ改善剤
EP0912523A1 (en) 1996-05-21 1999-05-06 PHARMACIA & UPJOHN COMPANY Aminoguanidine carboxylate lactams for the treatment of non-insulin-dependent diabetes mellitus
JP4317599B2 (ja) 1996-06-26 2009-08-19 武田薬品工業株式会社 徐放性製剤
DK1093370T3 (da) 1998-06-30 2006-05-22 Takeda Pharmaceutical Farmaceutisk præparat til behandling af diabetes
EP1656945A1 (en) 1999-06-05 2006-05-17 The Board Of Trustees Of The Leland Stanford Junior University Pharmaceutical composition comprising oligoarginine
US6605115B1 (en) 1999-06-05 2003-08-12 Board Of Trustees Of The Leland Stanford Junior University Method and composition for inhibiting cardiovascular cell proliferation
US6242491B1 (en) 1999-06-25 2001-06-05 Rima Kaddurah-Daouk Use of creatine or creatine compounds for skin preservation
US20020082448A1 (en) 1999-11-08 2002-06-27 The Upjohn Company Aminoguanidine carboxylates for the treatment of non-insulin-dependent diabetes mellitus
CA2456964A1 (en) 2001-08-08 2003-02-20 Merck & Co., Inc. Melanin-concentrating hormone antagonists
JP2005518346A (ja) 2001-11-07 2005-06-23 メディカル リサーチ カウンセル ドパミン作動性ニューロンの調節
CA2473229A1 (en) 2002-01-09 2003-07-24 Merck & Co., Inc. Selective melanin-concentrating hormone type -1 receptor agonists
US20120245211A1 (en) 2002-06-04 2012-09-27 Children's Hospital Medical Center Methods of Treating Cognitive Dysfunction by Modulating Brain Energy Metabolism
EP1567180A4 (en) 2002-06-04 2010-03-10 Avicena Group Inc METHOD FOR THE TREATMENT OF COGNITIVE DYSFUNCTION BY MODULATING THE CHANGE OF ENERGY REPLACEMENT IN THE BRAIN
GB0302882D0 (en) 2003-02-07 2003-03-12 Univ Cardiff Improvements in or relating to agents for the treatment of cardiovascular dysfunction and weight loss
EP1746099A1 (en) 2004-12-23 2007-01-24 DeveloGen Aktiengesellschaft Mnk1 or Mnk2 inhibitors
JP4865251B2 (ja) 2005-05-09 2012-02-01 株式会社 資生堂 不全角化抑制剤、毛穴縮小剤及び皮膚外用組成物
EP1909601B1 (de) 2005-08-02 2013-05-22 AlzChem Trostberg GmbH Flüssig-formulierung auf basis einer guanidinoessigsäure-komponente
WO2008054544A2 (en) 2006-05-22 2008-05-08 Immune Disease Institute, Inc. Method for delivery across the blood brain barrier
WO2008043024A2 (en) 2006-10-04 2008-04-10 Kalypsys, Inc. Oral pharmaceutical formulation comprising a sulfonyl bicyclic modulator of ppar for the treatment of disease
BRPI0720105A2 (pt) 2006-12-11 2014-10-07 Kempharm Inc Conjugados de aminoácido não padrões de anfetamina e processos para fabricação e uso dos mesmos
DE102007004781A1 (de) 2007-01-31 2008-08-07 Alzchem Trostberg Gmbh Verwendung von Guanidinoessigsäure(-Salzen) zur Herstellung eines gesundheitsfördernden Mittels
BRPI0807157A2 (pt) 2007-02-08 2014-04-29 Kempharm Inc Pró-farmacos hidrófilos polares de anfetamina e outros estimulantes e processos para fabricação e uso dos mesmos
EP2197890A1 (en) 2007-09-07 2010-06-23 Gencia Corporation Mitochondrial compositions and uses thereof
WO2009098142A1 (en) 2008-02-06 2009-08-13 Helm Ag Prasugrel salts with improved properties
FR2940077B1 (fr) 2008-12-19 2012-07-20 Oreal Procede de coloration eclaircissante de matieres keratiniques mettant en oeuvre une composition anhydre colorante comprenant un agent alcalin et une composition oxydante.
JP5711883B2 (ja) 2008-12-19 2015-05-07 ロレアル 脂肪物質に富む水性組成物の存在下で、淡色化し、あるいは淡色化直接染色し、あるいは酸化染色する方法、及びそのためのデバイス
FR2940104B1 (fr) 2008-12-19 2011-08-19 Oreal Procede de traitement des cheveux mettant en oeuvre une emulsion directe comprenant un agent oxydant et une composition contenant un agent alcalin
JP5866137B2 (ja) 2009-04-30 2016-02-17 ロレアル アミノトリアルコキシシランまたはアミノトリアルケニルオキシシラン化合物を含む組成物を用いたヒトケラチン繊維の明色化および／または着色ならびに装置
WO2011031308A1 (en) 2009-09-09 2011-03-17 Cytokinetics, Incorporated Novel combinations
EP2477643A1 (en) 2009-09-18 2012-07-25 Novo Nordisk A/S Long-acting y2 receptor agonists
FR2954160B1 (fr) 2009-12-22 2012-03-30 Oreal Composition de coloration ou d'eclaircissement comprenant un corps gras et un polymere amphotere
CA2785846C (en) 2009-12-31 2015-07-07 Kempharm, Inc. Amino acid conjugates of quetiapine, process for making and using the same
DE102010012199A1 (de) 2010-03-19 2011-09-22 Fresenius Medical Care Deutschland Gmbh Molekular geprägte Polymere für die Eliminierung von Metaboliten
FR2958161B1 (fr) 2010-04-02 2012-04-27 Oreal Procede de traitement des cheveux mettant en oeuvre une emulsion directe comprenant un agent oxydant et une emulsion directe contenant un agent alcalin
ES2713873T3 (es) 2010-04-16 2019-05-24 Nuevolution As Complejos bifuncionales y métodos para hacer y utilizar tales complejos
US20110262359A1 (en) 2010-04-21 2011-10-27 Jenkins Thomas E Compositions comprising enzyme-cleavable prodrugs of active agents and inhibitors thereof
US20110262355A1 (en) 2010-04-21 2011-10-27 Jenkins Thomas E Compositions comprising enzyme-cleavable opioid prodrugs and inhibitors thereof
EP2560490A1 (en) 2010-04-21 2013-02-27 Signature Therapeutics, Inc. Compositions comprising enzyme-cleavable prodrugs of active agents and inhibitors thereof
EP2560489A4 (en) 2010-04-21 2014-01-22 Signature Therapeutics Inc COMPOSITIONS WITH ENZYMSPALTBAR OPIOID PRODRUGS AND HEMMER FOR THIS
WO2011133348A1 (en) 2010-04-21 2011-10-27 Pharmacofore, Inc. Compositions comprising enzyme-cleavable amphetamine prodrugs and inhibitors thereof
RU2012151500A (ru) 2010-05-03 2014-06-10 Дженентек, Инк. Композиции и способы, пригодные для снижения вязкости белковосодержащих составов
US20130281410A1 (en) 2010-05-13 2013-10-24 University Of Utah Research Foundation Methods for the treatment of psychiatric disorders
EP2399885A1 (en) 2010-06-22 2011-12-28 Ulrich Dietz Device and method for solubilizing, separating, removing and reacting carboxylic acids in aqueous or organic solutions by means of micro- or nanoemulsification
WO2012024611A1 (en) 2010-08-20 2012-02-23 Natural Alternatives International, Inc. Methods of treating sarcopenia and frailty
WO2012047630A2 (en) 2010-09-27 2012-04-12 Martin Teintze N-alkyl or n-aryl substituted guanide and biguanide compounds and methods of their use
US8765115B2 (en) 2010-12-01 2014-07-01 National Institute of Agrobiological Scienses Method of treatment of gastrointestinal disorders with IL-10
BR112013022946A2 (pt) 2011-03-09 2017-07-18 Signature Therapeutics Inc pró-fármacos de agentes ativos com ligantes heterocíclocos
WO2012122420A2 (en) 2011-03-09 2012-09-13 Pharmacofore, Inc. Opioid prodrugs with heterocyclic linkers
US20120232066A1 (en) 2011-03-09 2012-09-13 Jenkins Thomas E Compositions for reducing risk of adverse events caused by drug-drug interactions
WO2012138214A1 (en) 2011-04-08 2012-10-11 Brewster Lizzy Maritza Beta-guanidinopropionic acid for the treatment of hypertension
WO2012173846A2 (en) 2011-06-06 2012-12-20 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
CN102850242A (zh) * 2011-06-27 2013-01-02 天津天成制药有限公司 胍基丙酸硝酸盐的制备方法
US8427223B2 (en) 2011-07-19 2013-04-23 Lsi Corporation Voltage level translator circuit for reducing jitter
MY162499A (en) 2011-07-28 2017-06-15 Kempharm Inc Methylphenidate-prodrugs, processes of making and using the same
CN104039342A (zh) 2011-10-18 2014-09-10 爱勒让治疗公司 拟肽大环化合物
FR2983407B1 (fr) 2011-12-06 2014-01-03 Oreal Composition aqueuse riche en huile et son utilisation dans un procede de coloration d'oxydation ou de decoloration
NZ627528A (en) 2012-02-15 2016-05-27 Aileron Therapeutics Inc Peptidomimetic macrocycles
HK1205454A1 (en) 2012-02-15 2015-12-18 Aileron Therapeutics, Inc. Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
AU2013273138B2 (en) 2012-06-05 2017-06-15 Neuroderm Ltd Compositions comprising apomorphine and organic acids and uses thereof
WO2013189910A1 (en) 2012-06-22 2013-12-27 Basf Se Multicomponent crystals comprising imatinib mesilate and selected co-crystal formers
CN114306315A (zh) 2012-10-31 2022-04-12 洛克菲勒大学 结肠癌的治疗和诊断
FR2997846B1 (fr) 2012-11-09 2023-10-20 Oreal Composition comprenant un derive dicarbonyle et un acide, le procede de lissage des fibres keratiniques a partir de cette composition
WO2014138492A1 (en) 2013-03-08 2014-09-12 Solan, LLC Methods for fabricating graphite-based structures and devices made therefrom
CN103288685B (zh) * 2013-07-03 2015-02-18 郭礼强 一种3-胍基丙酸的制备方法
US20170056352A1 (en) 2015-08-25 2017-03-02 Rgenix, Inc. PHARMACEUTICALLY ACCEPTABLE SALTS OF beta-GUANIDINOPROPIONIC ACID WITH IMPROVED PROPERTIES AND USES THEREOF
WO2018160178A1 (en) 2017-03-01 2018-09-07 Rgenix, Inc. Pharmaceutically acceptable salts of b-guanidinopropionic acid with improved properties and uses thereof

Similar Documents

Publication Publication Date Title
JP2018531280A5 (enExample)
JP2015512942A5 (enExample)
JP2021530565A5 (enExample)
KR20120059540A (ko) Ｃ－ｍｅｔ 조절제를 사용하는 방법
JP2017520612A (ja) 抗がん剤としての官能化され置換されたインドール
JP2016528179A5 (enExample)
JP2013503134A5 (enExample)
TW200808726A (en) Novel polymorph forms of (2S)-(4E)-N-methyl-5-[3-(5-isopropoxypyridin)yl]-4-penten-2-amine
TW202200594A (zh) 一種glp-1受體激動劑的晶型a及其製備方法
JP2014524476A5 (enExample)
JP2016513704A5 (enExample)
JP2016537326A5 (enExample)
JP2020521732A5 (enExample)
JP2019516749A5 (enExample)
RU2018103172A (ru) Кристаллическая фумаратная соль (s)-[3,4-дифтор-2-(2-фтор-4-йодфениламино)фенил][3-гидрокси-3-(пиперидин-2-ил)азетидин-1-ил]метанона
JP2021501766A5 (enExample)
US20210130333A1 (en) Crystal of benzofuran derivative free base and preparation method
JP2016510768A5 (enExample)
JP2015516425A5 (enExample)
RU2013120549A (ru) Новые кристаллические формы натриевой соли(4-{4-[5-(6-трифторметил-пиридин-3-иламино) пиридин-2-ил] фенил} циклогексил) уксусной кислоты
RU2012136148A (ru) Новая кристаллическая форма производного циклопропилбензамида
JP2011515421A5 (enExample)
CA3140231A1 (en) 3-aryloxyl-3-five-membered heteroaryl-propylamine compound, and crystal form and use thereof
CN111989329A (zh) 氘代3-(4,5-取代氨基嘧啶)苯基化合物单甲磺酸盐晶型及其制备方法
RU2015113277A (ru) Кристаллическтие соединения